Skip to content
Clinical Trials – home
LithuaniaBack to Lithuania

Clinical trials in Klaipeda

61 clinical trials in Klaipeda, Lithuania. Every trial is listed in the EU Clinical Trials Register and updated daily.

LithuaniaOur site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)
Klaipeda at a glance
61
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Klaipeda

Open in trial search
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bi 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Other cities in Lithuania

The busiest research cities in the country

All 10 cities in Lithuania

Clinical research in Klaipeda

What the registry says about research in the country

01 Autoimmune Conditions

Innovative research focusing on systemic sclerosis, psoriatic arthritis, and ulcerative colitis. Studies are evaluating novel therapies including efgartigimod and sonelokimab to improve patient outcomes.

  • Skin sclerosis treatment
  • Joint inflammation management
  • Gastrointestinal disorders

These trials aim to develop more effective treatments for chronic inflammatory conditions affecting multiple body systems.

02 Neurological Disorders

Groundbreaking studies in multiple sclerosis treatment, particularly focusing on relapsing-remitting forms. Research includes comparative studies of new biologics and established treatments.

  • Brain lesion reduction
  • Disease progression management
  • Long-term treatment efficacy

Clinical trials are exploring innovative approaches to improve neurological function and quality of life.

03 Cardiovascular Research

Studies targeting heart failure and atherosclerotic cardiovascular disease, with emphasis on preventing major adverse cardiac events and improving heart function.

  • Stroke prevention
  • Heart failure management
  • Cardiovascular risk reduction

Research focuses on both preventive measures and treatment of established cardiovascular conditions.

04 Oncology Studies

Advanced research in prostate cancer and bladder cancer, evaluating new treatment approaches including targeted therapies and hormone treatments.

  • Non-invasive cancer treatments
  • Metastatic disease management
  • Novel therapeutic approaches

Trials aim to improve survival rates and quality of life for cancer patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).